Dapagliflozin, the SGLT-2 inhibitor approved for clinical use, was studied in the Dapagliflozin and Cardiovascular and Renal Outcomes in Patients with Heart Failure and Diabetes or Pre-diabetes (DAPA-HF) trial, which included patients with HF and preserved or mildly reduced ejection fraction [10]. The gene discussed is SLC5A2; the disease is hydrops fetalis.